Pipeline Olive
Pathway | Program | Indication(s) | Discovery | Pre-Clinical | Clinical | Next Milestone |
Rights* |
---|---|---|---|---|---|---|---|
|
|||||||
IL–1R/ TLR |
IRAK4 | HS (Focus), AD, RA, Others | KT-474 | ![]() |
|||
Next Generation | ![]() |
||||||
IRAKIMiD (IRAK4, Ikaros, Aiolos) |
MYD88 MT DLBCL |
![]() |
|||||
JAK/ STAT |
STAT3 | Liquid, Solid Tumors |
![]() |
||||
STAT3 | Autoimmune, Fibrotic Diseases | ![]() |
|||||
|
|||||||
Pegasus Platform | Internal | Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications | ![]() |
||||
Partnered | Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program | ![]() ![]() |
|||||
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology | ![]() ![]() |
||||||
|
Oncology
Immunology-Inflammation
*Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.
Pathway | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IL-1R/TLR | ||||||||||||||||||
Program | Indication(s) | Rights* | ||||||||||||||||
|
||||||||||||||||||
IRAK4 | HS (Focus), AD, RA, Others | ![]() ![]() |
||||||||||||||||
|
||||||||||||||||||
IRAKIMiD (IRAK4, Ikaros, Aiolos) | MYD-88 MT DLBCL | ![]() |
||||||||||||||||
|
||||||||||||||||||
Pathway | ||||||||||||||||||
JAK/STAT | ||||||||||||||||||
Program | Indication(s) | Rights* | ||||||||||||||||
|
||||||||||||||||||
STAT3 | Liquid,Solid Tumors | ![]() |
||||||||||||||||
|
||||||||||||||||||
STAT3 | Autoimmune, Fibrotic Diseases | ![]() |
||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
Pathway | ||||||||||||||||||
Pegasus Platform | ||||||||||||||||||
Program | Indication(s) | Rights* | ||||||||||||||||
|
||||||||||||||||||
Internal | Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immunology-inflammation and genetically defined oncology indications | ![]() |
||||||||||||||||
Partnered | Our strategic collaboration with Sanofi includes a degrader program targeting IRAK4 and a second earlier stage program | ![]() ![]() |
||||||||||||||||
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology | ![]() ![]() |
|||||||||||||||||
|
Oncology
Immunology-Inflammation
*Kymera retains the option to participate in U.S. development and commercialization for Sanofi-partnered programs.